Ryan Sullivan

88PUBLICATIONS
604CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteinsTumour immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (88)

|Aug 11, 2026
ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.

|Jul 20, 2026
Frontline immunotherapy with response-guided subsequent treatment (FIRST) in cutaneous squamous cell carcinoma: a Bayesian causal analysis of dose intensity, early benefit, and treatment de-escalation.

|Jul 13, 2026
An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial.

|Jun 26, 2026
Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma.

|Jun 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

|Jun 24, 2026
Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance.

Pageof 15

Frequent Collaborators

13 joint publications

Genevieve Marie Boland

11 joint publications

Keith T Flaherty

11 joint publications

Meghan J Mooradian

9 joint publications

Priscilla K Brastianos